Table 3 Summary of results of clinical trials with combinations of anti-PD-1/PD-L1 with targeted therapy
Study name/code (NCT) | Study phase | Type of Cancer | Treatment | Patients evaluated for response | Time to first tumor assessment (weeks) | ORR by RECIST 1.1 criteria | ORR by immune-related response criteria | Patients treated beyond progression | Response rate after initial PD | First author and date of publication |
|---|---|---|---|---|---|---|---|---|---|---|
20,150,932 (NCT02636725) | 2 | Sarcoma | Pembrolizumab plus axitinib | 32 | 12 | 8 (25.0%) | 8 (25.0%) | 4 (12.5%) | Not reported | Wilky 2019 [74] |
A4061079 (NCT02133742) | 1b | RCC | Pembrolizumab plus axitinib | 52 | 12 | 38 (73.1%) | Not reported | 8 (15.4%) | 1 (1.9%) | Atkins 2018 [75] |
BTCRC-GU14–003 (NCT02348008) | 1b/2 | RCC | Pembrolizuamb plus bevacizumab | 58 | 6 | 33 (56.9%) | Not reported | 7 (12.1%) | Not reported | Dudek 2020 [76] |
CheckMate-012 (NCT01454102) | 1 | NSCLC | Nivolumab Plus erlotinib | 20 | 11 | 3 (15.0%) | Not reported | Not reported | 1 (5.0%) | Gettinger 2018 [77] |
GP28328 (NCT01633970) | 1b | RCC | Atezolizumab plus bevacizumab | 10 | 6 | 4 (40.0%) | Not reported | 2 (20.0%) | 1 (10.0%) | Wallin 2016 [78] |
KEYNOTE-146 (NCT02501096) | 1b/2 | Endometrial cancer | Pembrolizumab plus lenvatinib | 108 | 6 | 44 (40.7%) | 47 (43.5%) | Not reported | Not reported | Makker 2020 [79] |